Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting-Reference-Cited by-同舟云学术

Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – An observational study prospectively recording resource utilization in a Swedish healthcare setting

Published:2016-10 Issue: Volume:29 Page:140-146
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Olofsson Sara,Norrlid Hanna,Karlsson Eva,Wilking Ulla,Ragnarson Tennvall Gunnel

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference22 articles.

1. Cancer i siffror 2013-Populärvetenskapliga fakta om cancer;Socialstyrelsen, Cancerfonden,2013

2. The Medical Products Agency [Swedish: Läkemedelsverket]. Herceptin (trastuzumab) - ny indikation. http://www.lakemedelsverket.se/malgrupp/Halso–-sjukvard/Monografier-varderingar/Humanlakemedel-/Herceptin-trastuzumab–ny-indikation/ [Hämtad 2012-06-04]. 2012;23(3).

3. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial;Ismael;Lancet Oncol,2012

4. Assessment of time and practice resources required to provide weekly or monthly erythropoiesis-stimulating protein therapy to chronic kidney disease patients in the physician office setting;Bernardo;J Manag Care Pharm,2006

5. Importance of nondrug costs of intravenous antibiotic therapy;van Zanten;Crit Care,2003

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The burden of systemic therapy administration route in treating HER2-positive breast cancer (for patients, healthcare professionals, and healthcare system): a systematic literature review;Frontiers in Pharmacology;2024-08-19

2. Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors;The Oncologist;2024-07-09

3. Cost Evaluation of Subcutaneous Trastuzumab Versus Intravenous Trastuzumab for the Treatment of HER2-Positive Breast Cancer: Insights From Oncology Hospitals in Morocco;European Journal of Oncology Pharmacy;2024-07

4. Evaluating unmet needs in large-volume subcutaneous drug delivery: U.S. payer perspectives on a novel, large-volume on-body delivery system;Current Medical Research and Opinion;2024-05-17

5. Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial;Cancer Treatment and Research Communications;2024